A Study of Brepocitinib in Adults With Active, Non-Infectious, Non-Anterior Uveitis

Description

The purpose of this study is to determine the safety and efficacy of brepocitinib in participants with active, non-anterior (intermediate, posterior, or pan) non-infectious uveitis (NIU).

Conditions

Uveitis, Posterior, Uveitis, Intermediate, Uveitis

Talk to us

Study Overview

On this page

Study Details

Study overview

The purpose of this study is to determine the safety and efficacy of brepocitinib in participants with active, non-anterior (intermediate, posterior, or pan) non-infectious uveitis (NIU).

A Phase 3 Randomized, Double-Masked, Placebo-Controlled Study to Investigate the Safety and Efficacy of Oral Brepocitinib in Adults With Active, Non-Infectious Intermediate-, Posterior-, and Panuveitis

A Study of Brepocitinib in Adults With Active, Non-Infectious, Non-Anterior Uveitis

Condition
Uveitis, Posterior
Intervention / Treatment

-

Contacts and Locations

Phoenix

Clinical Trial Site, Phoenix, Arizona, United States, 85020

Bakersfield

Clinical Trial Site, Bakersfield, California, United States, 93309

Beverly Hills

Clinical Trial Site, Beverly Hills, California, United States, 90211

Fullerton

Clinical Trial Site, Fullerton, California, United States, 92835

Irvine

Clinical Trial Site, Irvine, California, United States, 92697

La Jolla

Clinical Trial Site, La Jolla, California, United States, 92093

Los Angeles

Clinical Trial Site, Los Angeles, California, United States, 90033

Los Angeles

Clinical Trial Site, Los Angeles, California, United States, 90095

Modesto

Clinical Trial Site, Modesto, California, United States, 95356

Sacramento

Clinical Trial Site, Sacramento, California, United States, 92825

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Adult subjects (18-75 years old)
  • * Diagnosis of non-infectious uveitis (intermediate uveitis, posterior uveitis, or panuveitis)
  • * Active uveitic disease in at least 1 eye
  • * Weight \> 40 kg with a body mass index ≤ 40 kg/m2
  • 1. Lymphoproliferative disorder
  • 2. active malignancy
  • 3. cancer within 5 years prior to screening (exceptions for basal cell carcinoma, squamous cell carcinoma, ductal carcinoma in situ of the breast, carcinoma in situ of the uterine cervix, or thyroid carcinoma.)
  • 4. thrombosis orand cerebrovascularardiovascular ischemic event disease within the last 12 months
  • 5. a high risk for herpes zoster reactivation
  • 6. active or recent infections

Ages Eligible for Study

18 Years to 75 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Priovant Therapeutics, Inc.,

Study Record Dates

2028-02-01